The cellular response to DNA damage induced by the enediynes C-1027 and neocarzinostatin includes hyperphosphorylation and increased nuclear retention of replication protein a (RPA) and trans inhibition of DNA replication.
This study examined the cellular response to DNA damage induced by antitumor enediynes C-1027 and neocarzinostatin. Treatment of cells with either agent induced hyperphosphorylation of RPA32, the middle subunit of replication protein A, and increased nuclear retention of RPA. Nearly all of the RPA32 that was not readily extractable from the nucleus was hyperphosphorylated, compared to < or =50% of the soluble RPA. Enediyne concentrations that induced RPA32 hyperphosphorylation also decreased cell-free SV40 DNA replication competence in extracts of treated cells. This decrease did not result from damage to the DNA template, indicating trans-acting inhibition of DNA replication. Enediyne-induced RPA hyperphosphorylation was unaffected by the replication elongation inhibitor aphidicolin, suggesting that the cellular response to enediyne DNA damage was not dependent on elongation of replicating DNA. Neither recovery of replication competence nor reversal of RPA effects occurred when treated cells were further incubated in the absence of drug. C-1027 and neocarzinostatin doses that caused similar levels of DNA damage resulted in equivalent increases in RPA32 hyperphosphorylation and RPA nuclear retention and decreases in replication activity, suggesting a common response to enediyne-induced DNA damage. By contrast, DNA damage induced by C-1027 was at least 5-fold more cytotoxic than that induced by neocarzinostatin.
McHugh
M M
MM
Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, New York 14263, USA.
Yin
X
X
Kuo
S R
SR
Liu
J S
JS
Melendy
T
T
Beerman
T A
TA
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000633:toxicity*; D000903:Antibiotics, Antineoplastic / Q000633:toxicity; D015153:Blotting, Western; D002461:Cell Line, Transformed / Q000187:drug effects / Q000378:metabolism; D002467:Cell Nucleus / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D002474:Cell-Free System / Q000187:drug effects; D004247:DNA / Q000037:antagonists & inhibitors* / Q000096:biosynthesis; D004249:DNA Damage; D004261:DNA Replication / Q000187:drug effects*; D004279:DNA, Viral / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D004268:DNA-Binding Proteins / Q000378:metabolism*; D004591:Electrophoresis, Polyacrylamide Gel; D053281:Enediynes; D006801:Humans; D007424:Intracellular Fluid / Q000187:drug effects / Q000378:metabolism; D010766:Phosphorylation / Q000187:drug effects; D051716:Replication Protein A; D013539:Simian virus 40 / Q000235:genetics; D012995:Solubility; D013698:Templates, Genetic; D015533:Transcriptional Activation / Q000187:drug effects*; D009353:Zinostatin / Q000031:analogs & derivatives / Q000633:toxicity*
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000903:Antibiotics, Antineoplastic; D004279:DNA, Viral; D004268:DNA-Binding Proteins; D053281:Enediynes; C497167:RPA1 protein, human; D051716:Replication Protein A; C058024:C 1027; C032372:neocarzinostatin chromophore; D004247:DNA; D009353:Zinostatin